Verbruggen AM[au] - Search Results

Year	Number of Results
1980	1
1983	1
1985	1
1986	2
1990	1
1992	2
1993	3
1994	3
1995	5
1996	2
1997	5
1998	4
1999	5
2000	3
2001	2
2003	6
2004	1
2005	3
2006	5
2007	7
2008	2
2009	1
2010	1
2011	3
2012	2
2013	3
2014	1
2015	3
2016	1
2017	1
2018	1
2024	0

1

Impurity profiling of N,N'-ethylenebis-l-cysteine diethyl ester (Bicisate).

Wahl O, Cleynhens J, Verbruggen AM, Holzgrabe U. Wahl O, et al. Among authors: verbruggen am. J Pharm Biomed Anal. 2018 Feb 20;150:132-136. doi: 10.1016/j.jpba.2017.11.078. Epub 2017 Dec 5. J Pharm Biomed Anal. 2018. PMID: 29223061

2

The 68Ge/ 68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine?

Breeman WA, Verbruggen AM. Breeman WA, et al. Among authors: verbruggen am. Eur J Nucl Med Mol Imaging. 2007 Jul;34(7):978-81. doi: 10.1007/s00259-007-0387-4. Eur J Nucl Med Mol Imaging. 2007. PMID: 17333177 Free PMC article. No abstract available.

3

Ultrasonographic diagnosis of persistent hyperplastic tunica vasculosa lentis/persistent hyperplastic primary vitreous in two dogs.

Boroffka SA, Verbruggen AM, Boevé MH, Stades FC. Boroffka SA, et al. Among authors: verbruggen am. Vet Radiol Ultrasound. 1998 Sep-Oct;39(5):440-4. doi: 10.1111/j.1740-8261.1998.tb01632.x. Vet Radiol Ultrasound. 1998. PMID: 9771597 Review.

4

Surveillance of aminoglycoside resistance. European data.

Van Landuyt HW, Boelaert J, Glibert B, Gordts B, Verbruggen AM. Van Landuyt HW, et al. Among authors: verbruggen am. Am J Med. 1986 Jun 30;80(6B):76-81. doi: 10.1016/0002-9343(86)90483-3. Am J Med. 1986. PMID: 3089007

5

[Voorjaarsdagen 2007].

Verbruggen AM, Werners A, Yokoi M. Verbruggen AM, et al. Tijdschr Diergeneeskd. 2007 Apr 1;132(7):270-1, 273, 275. Tijdschr Diergeneeskd. 2007. PMID: 17458492 Dutch. No abstract available.

6

Radiopharmaceuticals: state of the art.

Verbruggen AM. Verbruggen AM. Eur J Nucl Med. 1990;17(6-8):346-64. doi: 10.1007/BF01268027. Eur J Nucl Med. 1990. PMID: 2286208 Review.

7

Preclinical evaluation of [11C]NE40, a type 2 cannabinoid receptor PET tracer.

Evens N, Vandeputte C, Coolen C, Janssen P, Sciot R, Baekelandt V, Verbruggen AM, Debyser Z, Van Laere K, Bormans GM. Evens N, et al. Among authors: verbruggen am. Nucl Med Biol. 2012 Apr;39(3):389-99. doi: 10.1016/j.nucmedbio.2011.09.005. Epub 2011 Dec 11. Nucl Med Biol. 2012. PMID: 22154685

8

Technetium-99m-L,L-ethylenedicysteine scintigraphy in patients with renal disorders.

Gupta NK, Bomanji JB, Waddington W, Lui D, Costa DC, Verbruggen AM, Ell PJ. Gupta NK, et al. Among authors: verbruggen am. Eur J Nucl Med. 1995 Jul;22(7):617-24. doi: 10.1007/BF01254562. Eur J Nucl Med. 1995. PMID: 7498222 Clinical Trial.

9

Measurement of plasma volume using 99Tc(m)-labelled DMP-HSA.

du Raan H, Lötter MG, Harris GW, van Aswegen A, Otto AC, Nel MG, Badenhorst PN, Verbeke KA, Verbruggen AM. du Raan H, et al. Among authors: verbruggen am. Nucl Med Commun. 2000 Jun;21(6):539-44. doi: 10.1097/00006231-200006000-00007. Nucl Med Commun. 2000. PMID: 10894563

10

3'-99mTc-labeling and biodistribution of a CAPL antisense oligodeoxynucleotide.

Hjelstuen OK, Tønnesen HH, Bremer PO, Verbruggen AM. Hjelstuen OK, et al. Among authors: verbruggen am. Nucl Med Biol. 1998 Oct;25(7):651-7. doi: 10.1016/s0969-8051(98)00040-7. Nucl Med Biol. 1998. PMID: 9804046

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

74 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year